142 related articles for article (PubMed ID: 11316652)
1. Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions.
Zahm JM; Debordeaux C; Maurer C; Hubert D; Dusser D; Bonnet N; Lazarus RA; Puchelle E
Am J Respir Crit Care Med; 2001 Apr; 163(5):1153-7. PubMed ID: 11316652
[TBL] [Abstract][Full Text] [Related]
2. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
King M; Dasgupta B; Tomkiewicz RP; Brown NE
Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
[TBL] [Abstract][Full Text] [Related]
3. Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum.
Guichard MJ; Kinoo D; Aubriot AS; Bauwens N; Gougué J; Vermeulen F; Lebecque P; Leal T; Vanbever R
Clin Sci (Lond); 2018 Jul; 132(13):1439-1452. PubMed ID: 29871879
[TBL] [Abstract][Full Text] [Related]
4. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
5. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase.
Dasgupta B; King M
Pediatr Pulmonol; 1996 Sep; 22(3):161-6. PubMed ID: 8893254
[TBL] [Abstract][Full Text] [Related]
6. DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: in vitro effects of mucolytics.
Perks B; Shute JK
Am J Respir Crit Care Med; 2000 Nov; 162(5):1767-72. PubMed ID: 11069810
[TBL] [Abstract][Full Text] [Related]
7. [Effect of rhDNase on rheologic properties and transport capacity of mucus in cystic fibrosis].
Puchelle E; Zahm JM
Arch Pediatr; 1995 Jul; 2(7):670-3. PubMed ID: 7663658
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus.
Zahm JM; Girod de Bentzmann S; Deneuville E; Perrot-Minnot C; Dabadie A; Pennaforte F; Roussey M; Shak S; Puchelle E
Eur Respir J; 1995 Mar; 8(3):381-6. PubMed ID: 7789481
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
Ramsey BW; Astley SJ; Aitken ML; Burke W; Colin AA; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Schidlow DV
Am Rev Respir Dis; 1993 Jul; 148(1):145-51. PubMed ID: 8317790
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.
Shak S; Capon DJ; Hellmiss R; Marsters SA; Baker CL
Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9188-92. PubMed ID: 2251263
[TBL] [Abstract][Full Text] [Related]
11. Airway inflammation after treatment with aerosolized deoxyribonuclease in cystic fibrosis.
Henry RL; Gibson PG; Carty K; Cai Y; Francis JL
Pediatr Pulmonol; 1998 Aug; 26(2):97-100. PubMed ID: 9727759
[TBL] [Abstract][Full Text] [Related]
12. Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis.
Sanders NN; Franckx H; De Boeck K; Haustraete J; De Smedt SC; Demeester J
Thorax; 2006 Nov; 61(11):962-8. PubMed ID: 17071834
[TBL] [Abstract][Full Text] [Related]
13. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics.
Broughton-Head VJ; Smith JR; Shur J; Shute JK
Pulm Pharmacol Ther; 2007; 20(6):708-17. PubMed ID: 17055310
[TBL] [Abstract][Full Text] [Related]
14. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.
Suri R; Marshall LJ; Wallis C; Metcalfe C; Bush A; Shute JK
Am J Respir Crit Care Med; 2002 Aug; 166(3):352-5. PubMed ID: 12153969
[TBL] [Abstract][Full Text] [Related]
15. Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus.
Pan CQ; Dodge TH; Baker DL; Prince WS; Sinicropi DV; Lazarus RA
J Biol Chem; 1998 Jul; 273(29):18374-81. PubMed ID: 9660804
[TBL] [Abstract][Full Text] [Related]
16. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis.
Shah PL; Scott SF; Knight RA; Hodson ME
Eur Respir J; 1996 Mar; 9(3):531-4. PubMed ID: 8730015
[TBL] [Abstract][Full Text] [Related]
17. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
Hodson ME
Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
[TBL] [Abstract][Full Text] [Related]
18. Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients.
Heijerman HG; van Rossem RN; Bakker W
Neth J Med; 1995 Jun; 46(6):293-7. PubMed ID: 7643945
[TBL] [Abstract][Full Text] [Related]
19. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
[TBL] [Abstract][Full Text] [Related]
20. Effects of rhDNase on purulent airway secretions in chronic bronchitis.
Puchelle E; Zahm JM; de Bentzmann S; Grosskopf C; Shak S; Mougel D; Polu JM
Eur Respir J; 1996 Apr; 9(4):765-9. PubMed ID: 8726943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
